Personal information

No personal information available

Activities

Works (7)

Impact of First-Line Osimertinib and Other EGFR-Tyrosine Kinase Inhibitors on Overall Survival in Untreated Advanced EGFR-Mutated Non-small Cell Lung Cancer in Japan: Updated Data from TREAD Project 01

Targeted Oncology
2024-11 | Journal article
Contributors: Makoto Hibino; Yoshinori Imamura; Rai Shimoyama; Tomoya Fukui; Ryuta Fukai; Akihiko Iwase; Yukihiro Tamura; Yusuke Chihara; Takafumi Okabe; Kiyoaki Uryu et al.
Source: check_circle
Crossref

Rationale and protocol design of a phase II study of first-line osimertinib treatment for patients with poor performance status and EGFR mutation-positive non-small cell lung cancer (OPEN/TORG2040)

BMC Cancer
2022-12-15 | Journal article
Contributors: Tomoya Fukui; Jiichiro Sasaki; Satoshi Igawa; Akiko Kada; Toshiki I. Saito; Yoshihito Kogure; Hiroaki Okamoto; Katsuhiko Naoki
Source: check_circle
Crossref

Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non‐small cell lung cancer prior to the approval of durvalumab

Thoracic Cancer
2020-04 | Journal article
Contributors: Tomoya Fukui; Shinji Hosotani; Itaru Soda; Takahiro Ozawa; Seiichiro Kusuhara; Mikiko I. Kakegawa; Masashi Kasajima; Yasuhiro Hiyoshi; Satoshi Igawa; Masanori Yokoba et al.
Source: check_circle
Crossref

Activity of Nivolumab and Utility of Neutrophil-to-Lymphocyte Ratio as a Predictive Biomarker for Advanced Non–Small-Cell Lung Cancer: A Prospective Observational Study

Clinical Lung Cancer
2019-05 | Journal article
Contributors: Tomoya Fukui; Yuriko Okuma; Yoshiro Nakahara; Sakiko Otani; Satoshi Igawa; Masato Katagiri; Hisashi Mitsufuji; Masaru Kubota; Yasuhiro Hiyoshi; Mikiko Ishihara et al.
Source: check_circle
Crossref

Evaluation of osimertinib efficacy according to body surface area and body mass index in patients with non‐small cell lung cancer harboring an EGFR mutation: A prospective observational study

Thoracic Cancer
2019-04 | Journal article
Contributors: Taihei Ono; Satoshi Igawa; Takahiro Ozawa; Masashi Kasajima; Mikiko Ishihara; Yasuhiro Hiyoshi; Seiichiro Kusuhara; Noriko Nishinarita; Tomoya Fukui; Masaru Kubota et al.
Source: check_circle
Crossref

Questionnaire survey on patient awareness of invasive rebiopsy in advanced non‐small cell lung cancer

Thoracic Cancer
2019-03 | Journal article
Contributors: Tomoya Fukui; Mikiko Ishihara; Masashi Kasajima; Yasuhiro Hiyoshi; Yoshiro Nakahara; Sakiko Otani; Satoshi Igawa; Masanori Yokoba; Hisashi Mitsufuji; Masaru Kubota et al.
Source: check_circle
Crossref

Exploration of germline variants responsible for adverse events of crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer by target-gene panel sequencing

Lung Cancer
2019-02 | Journal article
Contributors: Hidenori Mizugaki; Akinobu Hamada; Tatsuhiro Shibata; Fumie Hosoda; Hiromi Nakamura; Yusuke Okuma; Takehito Shukuya; Shigeki Umemura; Atsushi Horiike; Tomoya Fukui et al.
Source: check_circle
Crossref